Figure 2 Figure 2A: Overall progression-free survival (PFS) for patients with advanced biliary tract cancer treated with apatinib monotherapy as a second-line regimen. The median PFS was 8 months.
Figure 2B: Progression-free survival (PFS) for patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GBC) treated with apatinib monotherapy as a second-line regimen. The median PFS in GBC group was 2.5 months and in CC group was 8 months, p=0.052

Figure 3 Images of a 65-year-old male patient with cholangiocarcinoma after treatment with apatinib monotherapy. Contrast-enhanced CT at baseline (A) showed an approximately 6.5*4 cm cholangiocarcinoma. CT images at 1 month (B) and 2.5 months (C) after baseline showed the tumor shrunk to 4.6*3.5 cm and 3.2*2 cm, respectively.

Category	Definition
Complete response (CR)	Complete disappearance of all target lesions
Partial response (PR)	≥30 % decrease in tumor diameter from baseline
Stable disease (SD)	Small changes that do not meet the above criteria
Progressive disease (PD)	>20% increase in tumor diameter from baseline

Table 1: Four response categories.

Characteristics		Number of patients
Sex	Male	14
	Female	4
Age (years)	Median	55
	40-50	4
	50-60	9
	60-70	5
Metastatic site
From cholangiocarcino ma	Liver	2
	Retroperitoneal node	5
	Lungs	3
	Supraclavicular lymph node	2
From gallbladder cancer	Liver	2
	Gallbladder (locally advanced)	4
Initial treatment/ recurrence
Initial treatment		10
Post-surgery Recurrence		8
Gemcitabine (first-line medicine) therapy
Monotherapy		3
Gemcitabine-cisplatin		15
Initial dosage of apatinib (mg)
500		12
250 (dosage reduced from 500 within the first 10 days)		6

Table 2: Patient characteristics

Adverse events	Total, n%	Grade
Adverse events	Total, n%	G1-G2	G3
Hypertension	11 (61%)	7	4
Diarrhea	6 (33%)	5	1
Hand-foot syndrome	5 (28%)	4	1
Proteinuria	8 (44%)	7	1
Fatigue	13 (72%)	11	2
Liver dysfunction	2 (11%)	2	-
Anemia	2 (11%)	3	-
Neutropenia	2 (11%)	2	-
Thrombocytopenia	1(6%)	1	-

Table 3: Treatment-related adverse events: